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ABSTRACT. Chromosomal abnormalities and ZAP70 expression 
profile are two major independent prognostic markers in B-cell chronic 
lymphocytic leukemia. We investigated a possible correlation between 
these two markers. ZAP70 expression using real-time RT-PCR was 
examined in 20 B-cell chronic lymphocytic leukemia patients with 
del13q14, 13 patients with del11q22, 15 patients with trisomy 12, and 
16 patients with no detected chromosomal abnormalities. Molecular 
analysis revealed that ZAP70 expression in the del13q subgroup was 
the same as in the control group, while it increased 2.78-fold in the 
del11q subgroup and 2.95-fold in the trisomy 12 subgroup, compared to 
the 15 cases in the control group. Comparison of the mean and standard 
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deviation of the ZAP70 expression profile within the subgroups 
showed it to be highly variable among the individuals of the del11q and 
trisomy 12 subgroups, versus tight clustering for the del13q subgroup. 
Therefore, there is a correlation between del13q aberration, which has 
good prognosis with normal levels of ZAP70 expression. Due to a high 
degree of variation, no conformity is seen for del11q and trisomy 12 
subgroups, making this grouping poor for prognostic discrimination. 
As a result, neither of these markers can serve as sole discriminators to 
determine the course of the disease; the use of both markers improves 
prognostic assessment.
Key words: Chronic lymphocytic leukemia; ZAP70; CD38; 
Cytogenetic abnormalities
INTRODUCTION
B-cell chronic lymphocytic leukemia (B-CLL), a hematopoietic neoplasm of B-
lymphocytes, is the most common form of leukemia in adult life. One of the most important 
research issues in B-CLL is to identify prognostic factors that can predict the clinical course 
of the disease. Recently, several prognostic factors have emerged. Mutational status of the 
immunoglobulin heavy chain variable region (IgVH) is one of the most reliable prognostic 
markers in B-CLL. Unmutated IgVH regions are associated with poor prognosis, whereas 
mutated IgVH regions represent a good prognosis (Hamblin et al., 1999). However, muta-
tional analysis of IgVH is both laborious and expensive, and it is inaccessible for many clini-
cal genetic laboratories. Therefore, the identification of a surrogate marker for mutational 
status of IgVH has become an important goal.
Because measuring CD markers is rapid and convenient by flow cytometry, they be-
came the first biological markers to be extensively studied as a surrogate marker. CD38 and 
CD23 were two markers that were correlated with IgVH mutational status, but their prognostic 
value has been the subject of many controversies (Damle et al., 1999; Hamblin et al., 2002; 
Krober et al., 2002; Schroers et al., 2005) and they required further investigation. Gene ex-
pression profiling with cDNA microarray revealed that several expressed genes can correlate 
with IgVH mutational status in B-CLL patients. ZAP70 (70-kDa zeta-chain associated protein 
kinase), a member of the Syk protein tyrosine kinase family, is one of the most promising 
surrogate markers in this regard (Crespo et al., 2003; Ferrer et al., 2004). High expression of 
ZAP70 was correlated with unmutated IgVH subtype, and low expression of ZAP70 was ob-
served in mutated IgVH subtype (Orchard et al., 2004; Catherwood et al., 2006).
However, the biological role of ZAP70 in B-CLL is still unknown, and it does not 
completely correlate with IgVH mutational status. Therefore, it cannot be taken as the sole 
marker with hundred percent accuracy.
Additionally, chromosomal abnormalities have a prognostic role in B-CLL. The most 
common chromosomal abnormalities in B- also CLL are deletions at 13q14 (about 50%), 
11q22 (7-20%) and 17p13 (about 10%) and trisomy 12 (15-25%). Deletion of 13q14 is associ-
ated with good prognosis, whereas deletion in 11q22 and 17q13 are said to have poor progno-
sis. Trisomy 12 is thought to confer an intermediate prognosis (Moreno and Montserrat 2008).
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In the present study, CD markers and ZAP70 mRNA expression level were deter-
mined in the del13q14, del11q22 and trisomy 12 subgroups of Iranian B-CLL patients to in-
vestigate prognostic value of CD38 and ZAP70 and the possible relationship between ZAP70 
expression and CD38 and cytogenetic subgroups.
MATERIAL AND METHODS
Patients
The clinical diagnosis of B-CLL was made based on criteria defined by the National 
Cancer Institute Working Group (NCI-WG) (Cheson et al., 1988). The Ethics Committee of 
Tarbiat Modartes University approved the study, and samples were taken following informed 
consent. Samples from 64 patients who had been newly diagnosed with B-CLL or at least were 
taken off treatment for the past six months were included. Patients were staged at the time of 
diagnosis according to the Rai staging. Six patients were diagnosed at stage 0; 9 at stage I; 30 
at stage II; 14 at stage III, and 5 at stage IV. Forty-six were males and 18 cases were females. 
Patients were 42 to 81 years old. The median suffering time was 51.6 ± 1.3 months, ranging 
from 13 to 300 months. Mean and range of some hematological characteristics within the 
subgroups are summarized in Table 1.
Subgroup Platelet (106/mL) % Lymphocytes WBC (109/L)       RBC (109/mL)
    Mean Range Mean  Range Mean   Range Mean Range
Del13q   177 ± 10 89-271 68 ± 3.0 32-90 24 ± 2.3 11-47 4.4 ± 0.1 2.7-5.4
Del11q   158 ± 13 95-247 73 ± 4.8 38-93 38 ± 4.7 13-80 4.4 ± 0.2 3.0-5.7
Trisomy 12   160 ± 22 49-401 70 ± 3.5 38-89 45 ± 7.5     9-115 4.4 ± 1.9 3.2-5.7
Undetected   160 ± 22 61-415 79 ± 2.1 65-95 39 ± 7.2   19-121 4.3 ± 0.2 1.2-5.7
Total 171 ± 8 49-415 73 ± 1.7 32-95 41 ± 5.9     9-121 4.3 ± 0.9 1.2-5.7
WBC = whole blood cell; RBC = red blood cell.
Table 1. Some hematological characteristics of B-CLL patients.
After clinically diagnosed with B-CLL, patients were referred for routine cytogenetic 
evaluation. Following conventional chromosomal analysis and I-FISH study of patients’ bone 
marrow and/or peripheral blood with RB1, ATM and chromosome 12 centromeric probes, four 
groups emerged: 20 cases with del13q, 13 cases with del11q, 15 cases with trisomy 12, and 16 
patients with undetected chromosomal abnormality. These four groups were investigated for 
ZAP70 expression status. Fifteen normal individuals (age- and gender-matched) were simi-
larly analyzed as the control group. Peripheral blood was collected in EDTA tubes from the 
patients and individuals of the control group.
Immunophenotyping
Peripheral blood mononuclear cells were separated from heparinized venous blood by 
density gradient centrifugation using Ficoll-Paque. The cells were washed twice with phos-
phate-buffered saline (PBS) and were incubated with FITC-conjugated anti-mouse antibody 
(IQ-Products, The Netherlands) for: CD2, CD5, CD10, CD11c, CD19, CD20, CD22, CD23, 
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CD25, CD38, FMC7, and HLA-DR. The stained cells were sorted using the FACScan flow 
cytometer (Becton Dickinson, San Jose, CA, USA) and the data were analyzed using the 
CellQuest software.
RNA extraction and qualification
Two milliliters EDTA-preserved fresh whole blood was diluted with 2 mL sterile PBS 
and carefully transferred to 4 mL Ficoll-Paque (Biomol, The Netherlands). The new sample 
was centrifuged for 15 min at 2000 rpm. The buffy coat was isolated in a 1.5-mL Epen-
dorff microtube. After normalizing the specimens, total RNA was extracted from the buffy 
coat using the High Pure RNA Isolation kit (Roche, Germany) according to manufacturer 
instructions. The quality and concentration of the extracted RNA samples were spectrophoto-
metrically determined by measuring optical density at 260 and 280 nm (Genova Life Science 
Analyser-DNA, Jenway, England).
cDNA synthesis
First-strand cDNA was generated with the use of random hexamer primers and em-
ploying a commercially available kit (Revert Aid First-Strand cDNA Synthesis kit, Fermentas, 
Life sciences, Germany) following manufacturer instructions. For determining the accuracy 
of the cDNA synthesis reaction, cDNA was amplified by PCR with ZAP70 primers. The PCR 
products were then analyzed by electrophoresis on a 2% garose gel.
Gene expression analysis
A quantitative real-time RT-PCR method was established to determine ZAP70 expres-
sion. The amplification was performed with a real-time rotary analyzer (Rotor-Gene 6000, 
Corbett, Australia), and data were automatically analyzed by the Rotor-Gene software accord-
ing to the comparative ΔΔCt method at the end of reactions. cDNA sample from a 32-year-old 
healthy man was used as a calibrator. Housekeeping gene β-glucoronidase (GUSB) was used 
as the reference gene for normalization. One standard curve for ZAP70 and one for GUSB 
were obtained using 10-fold serial dilutions of the calibrator’s cDNA. Primers of ZAP70 and 
GUSB are shown in Table 2.
Gene Accession No. Amplification length Forward primer Reverse primer Ref.
ZAP70 NM-001079 187 bp 5'GTTGACTCATCCTCAGAGACGAATC 5'AGGTTATCGCGCTTCAGGAA (Kienle et al., 2005)
GUSB NM-000181 100 bp 5'GAAAATACGTGGTTGGAGAGCTCATT 5'CCGAGTGAAGATCCCCTTTTTA (Aerts et al., 2004)
Table 2. Characteristics of primers used for RQ-PCR in this study.
Real-time RT-PCR amplification was performed in a final reaction volume of 20 μL 
containing 2 μL target cDNA, 0.7 μL forward primer, 0.7 μL reverse primer, 4 μL master mix 
(LightCycler Fast Start DNA Master Sybr Green I, Roche, Germany) and 12.6 μL PCR-grade 
water. The thermal cycling conditions for both genes were 10 min at 95°C followed by 40 
cycles of denaturation at 94°C for 12 s, annealing at 60°C for 15 s and extension at 72°C for 
12 s. All reactions were in duplicate.
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Statistical analysis
Raw data were analyzed by means of the SPSS program version 15 software. One-
way ANOVA was used for determination of statistical significance of ZAP70 expression in 
cytogenetic subgroups versus the control group. When significant difference was established, 
three post hoc comparison tests (Tukey, Duncan and Scheffe) were utilized to categorize dif-
ferences. Statistical relationship between ZAP70 expression and Rai stages and CD38 was 
evaluated by a two-tailed Pearson correlation test. Differences with P less than 0.05 were 
considered to be statistically significant.
RESULTS
Flow cytometry for the mentioned markers was successfully performed on all pa-
tients’ blood samples. Mean and range of five distinctive B lymphocyte CD markers, i.e., CD5, 
CD19, CD20, CD23, and CD38, were collected from the patients’ profiles and are summarized 
in Table 3.
ZAP70 expression from 20 patients with del13q14, 13 patients with del 11q22, 15 
patients with trisomy 12, 16 undetected chromosomal abnormalities, and 15 control cases 
were performed by real-time PCR using cDNA samples. Melting curve analysis showed 
that all amplification products were of the expected size, without any genomic DNA con-
tamination.
The quality of amplification performance was evaluated from the standard curves 
generated from 10-fold serial dilutions of the calibrator’s cDNA. The efficiency value of the 
reactions ranged from 0.94 to 1.01 for ZAP70 and from 0.98 to 1.05 for GUSB. The cor-
relation coefficient of each amplification was very close to 1. The expression ratio between 
ZAP70 and GUSB was automatically produced at the end of each reaction for each sample by 
the RotoGene software. Pearson’s correlation test showed weak correlation between CD38 
and Rai stages (coefficient of 0.3 at 0.04 level), whereas highly significant correlation be-
tween ZAP70 expression and Rai stages (coefficient of 0.418 at 0.001 level).
Pearson’s correlation test between ZAP70 mRNA and CD38 markers revealed a weak 
correlation between ZAP70 mRNA and CD38 expression (0.236 at a 0.007 significance).
Statistical analysis of the expression ratio measured in cytogenetic subgroups pro-
duced the following results. Mean and standard deviation of the expression ratio in the con-
trol group was 1.007 and 0.320, respectively. These two parameters in the del13q subgroup 
were 0.8857 and 0.304, in the del11q subgroup 2.7838 and 1.23, in the trisomy 12 subgroup 
Subgroup CD5  CD19  CD20  CD23  CD38
 Mean Range Mean Range Mean Range Mean Range Mean Range
Del13q 53 ± 4.8 21-99 70 ± 4.2 38-97 54 ± 5.4 17-88 55 ± 4.0   6-85 24 ± 3.9 1-60
Del11q 43 ± 5.6   4-77 62 ± 6.9 16-92 61 ± 5.1 32-85 58 ± 6.2   1-82 41 ± 6.2 3-73
Trisomy 12 49 ± 7.8   2-94 73 ± 5.1 38-96 52 ± 7.3 11-88 55 ± 3.3 36-70 26 ± 4.7 2-59
Undetected 42 ± 6.8   4-93 65 ± 5.7 10-93 45 ± 7.4   2-95 45 ± 6.2   4-81 35 ± 6.3 1-84
Total 45 ± 3.2   2-99 68 ± 2.6 10-97 52 ± 3.2   2-95 52 ± 2.6   1-85 33 ± 2.7 1-84
Table 3. Mean and range of CD5, CD19, CD20, CD23, and CD38 within cytogenetic subgroups.
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2.9547 and 1.60, and in the undetected group 1.0013 and 0.339. The distribution of ZAP70 
expression ratio to GUSB in cytogenetic subgroups and the control group is shown in Figure 1.
ANOVA indicated that there was a significant difference in the distribution of ZAP70 
expression ratio between the cytogenetic subgroups and the control group. All three post hoc 
tests revealed similar results. They classified 3 cytogenetic subgroups and undetected and con-
trol groups (5 study groups in total) as two statistically significant subsets. Del113q subgroup, 
undetected and control groups were in one subset, while trisomy 12 and del11q subgroups were 
grouped in another subset. Results of these three statistical analyses are summarized in Table 4.
Figure 1. The histogram of ZAP70 expression within different study groups. Undet. = undetected group; Tri. 12 
=  trisomy 12.
Test Group Number    Subset for alpha = 0.05
   1 2
Tukey HSDa,b Del13q 20 0.8857 -
 Undetected 16 1.0013 -
 Control 15 1.0073 -
 Del11q 13 - 2.7838
 Trisomy 12 15 - 2.9547
Significance   0.995 0.983
Duncana,b Del13q 20 0.8857 -
 Undetected 16 1.0013 -
 Control 15 1.0073 -
 Del11q 13 - 2.7838
 Trisomy 12 15 - 2.9547
Significance   0.722 0.593
Scheffea,b Del13q 20 0.8857 -
 Undetected 16 1.0013 -
 Control 15 1.0073 -
 Del11q 13 - 2.7838
 Trisomy 12 15 - 2.9547
Significance   0.997 0.990
Means for groups in homogeneous subsets are displayed. aUses harmonic mean sample size = 15.607. bThe group 
sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not guaranteed.
Table 4. Statistical analysis of ZAP70 expression using three post hoc tests.
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The statistical analysis shown in Table 4 indicates that ZAP70 expression in the 
del13q subgroup and in the undetected group was the same as the control group, but it was 
overrepresented in trisomy 12 and del11q subgroups. ZAP70 expression had about 2.95- and 
2.78-fold overexpression in trisomy 12 and del11q subgroups, respectively.
DISCUSSION
The clinical staging systems proposed by Rai or Binet are the strongest and best 
validated predictors of clinical outcome in CLL. Both systems classify CLL patients into 
low, intermediate and high risk subgroups based on clinical observations and standard labora-
tory tests. Patients with early stage of the disease (Rai stages 0 and I or Binet stage A) have 
generally an indolent course with long survival or good prognosis, while advanced stage of 
disease (Rai stages III and IV or Binet stage C) shows an aggressive course with short sur-
vival or poor prognosis. Most potential prognostic markers have been shown to contribute to 
the information that correlates with clinical stages of the disease (Rai et al., 1975; Binet et 
al., 1981). Consequently, clinical staging systems are the mainstay for assessing prognosis in 
patients with CLL.
Independent prognostic value of CD38 expression was evaluated by Pearson’s cor-
relation test. There was a weak correlation between Rai stages and CD38 expression (correla-
tion coefficient of 0.3). The importance of CD38 as a prognostic marker has been the subject 
of many controversies. The data of this study agree with the research that did not strongly 
confirm CD38 prognostic impact (Hamblin et al., 2002; Krober et al., 2002).
On the other hand, ZAP70 expression showed a good correlation with Rai stages. 
This correlation indicated that the increased ZAP70 expression was correlated with the Rai 
grading scale, representing severity of the patient’s clinical condition. The Pearson coeffi-
cient value of 0.42 demonstrated that there is a direct relationship between disease progres-
sion and increased ZAP70 expression, and it may be considered a prognostic marker to assess 
a patient’s condition. The importance of ZAP70 as an independent prognostic marker has 
been shown in numerous earlier studies (Wiestner et al., 2003; Kim et al., 2004; Rassenti et 
al., 2004; Stamatopoulos et al., 2007).
Statistical analysis of ZAP70 and CD38 expression showed a very weak correlation 
between these two markers. This means that CD38 value is not in concordance with ZAP70 
expression value in patients. Based on the weak prognostic impact of CD38, good predictive 
value of ZAP70 expression and finally weak concordance of ZAP70 and CD38, it could be 
concluded that CD38 would not be a reliable prognostic marker in CLL and that simultaneous 
evaluation of CD38 and ZAP70 has no considerable clinical value in prognosis in CLL. This 
finding is in agreement with the earlier results of Ibrahim et al. (2001), Orchard et al. (2004) 
and Del Principe et al. (2006).
Next, the ZAP70 expression was analyzed in the cytogenetic subgroups and the con-
trol group using ANOVA. Except for the del11q subgroup, the other groups consisted of at 
least 15 individuals. This sample number was initially inferred by one-way ANOVA, for 
determining sample size using the MiniTab program. In three other research reports, sample 
size for each group was in this range between 15-20 individuals (Ibrahim et al., 2001; Kienle 
et al., 2005; van’t Veer et al., 2006; Chen et al., 2008). Therefore, the sample size was con-
sidered to be satisfactory.
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Statistical analysis of the ZAP70 expression profile within the cytogenetic subgroups 
indicated that expression in the del13q subgroup was similar to that of the control group, and 
the small difference between two mean values can be attributed to random sampling. Although 
the undetected subgroup showed a good clustering and similarity with the control group, its 
interpretation was impossible due to the fact that their chromosomal abnormalities were not 
known. However, expression within the two subgroups of del11q and trisomy 12 increased 
significantly. This observation was similar to the findings by other investigators (Kienle et al., 
2005; Schroers et al., 2005; Krober et al., 2006).
Comparison of means and standard deviations for the cytogenetic subgroups and 
the control group illustrated that standard deviations for the del13q subgroup and the control 
group were much smaller than those of del11q and trisomy 12 subgroups. As can be seen in 
Figure 1, the distribution of ZAP70 expression value within del11q and trisomy 12 subgroups 
has a great range compared to del13q and undetected subgroups with compact clustering. It 
can be concluded that contrary to the del13q subgroup, ZAP70 expression profile in the two 
poor prognosis subgroups of del11q and trisomy 12 is highly variable.
If a cut-off value for ZAP70 expression level is calculated by adding 3-fold standard 
deviation to the mean of the control group, the value 1.97 is obtained, for which only 10 pa-
tients from the del11q subgroup (77%) and 10 patients from the trisomy 12 subgroup (66.6%) 
showed higher expression. If borderline values are excluded, the patient number decreases. As 
a result, it can be concluded that the concordance between ZAP70 expression and cytogenetic 
subgroups is not a hundred percent and shows their independence.
According to the well-known prognostic significance of cytogenetic abnormalities 
and ZAP70 expression, good correlation of ZAP70 expression within cytogenetic subgroups, 
and moderate concordance of ZAP70 with cytogenetic subgroups, it could be inferred that 
combined analysis of the two mentioned markers could prognosticate the disease outcome 
more favorably and serve for precise definition of prognosis if the value of one predictor fac-
tor is doubtful.
In conclusion, according to this study, CD38 could not be regarded as a reliable prog-
nostic factor, and has a poor concordance with ZAP70 expression profile. Furthermore, si-
multaneous evaluation of CD38 and ZAP70 has no considerable prognostic value in B-CLL. 
However, the relationship between the cytogenetic subgroups and ZAP70 expression profile 
did show a considerable correlation: expression level in del13q subjects is similar to normal 
control individuals whereas its mean value is increased in del11q and trisomy 12 subgroups 
despite the variation between different patients. As a result, the study of these two independent 
prognostic factors shows significant concordance, which provides a better prognosis.
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